Findings
Background
Results
Registration and sequencing
Detected genomic alterations
Entry into phase I clinical trials
No. | Cancer type | Molecular alteration | Matched therapy | Response | Progression free survival (month) |
---|---|---|---|---|---|
1 | Bile duct |
FGFR2
| FGFR inhibitor | PD | 0.95 |
2 | Cervical |
PIK3CA
E542K | PI3K inhibitor | NE | 2.53 |
3 | Liver |
TSC1
| mTOR inhibitor | NE | 0.82 |
4 | Breast |
BRCA1
| PARP inhibitor | PR | 8.09 |
5 | Peritoneal |
BRCA1
| PARP inhibitor | SD | 7.17 |
6 | Cervical |
PIK3CA
E542K | AKT inhibitor | PD | 0.72 |
7 | Breast |
PIK3CA
H1047R | PI3K inhibitor | PR | 6.18 |
8 | Breast |
PIK3CA
E545K | PI3K inhibitor | SD | 2.80 |
9 | Breast |
PIK3CA
E545V | PI3K inhibitor | SD | 5.72 |
10 | Breast |
AKT1
E17K | AKT inhibitor | PR | 14.1 |
11 | Breast |
BRCA1
| PARP inhibitor | SD | 5.53 |